SG10201804260QA - Diagnostic assays and kits for detection of folate receptor 1 - Google Patents

Diagnostic assays and kits for detection of folate receptor 1

Info

Publication number
SG10201804260QA
SG10201804260QA SG10201804260QA SG10201804260QA SG10201804260QA SG 10201804260Q A SG10201804260Q A SG 10201804260QA SG 10201804260Q A SG10201804260Q A SG 10201804260QA SG 10201804260Q A SG10201804260Q A SG 10201804260QA SG 10201804260Q A SG10201804260Q A SG 10201804260QA
Authority
SG
Singapore
Prior art keywords
folate receptor
detection
diagnostic assays
kits
folri
Prior art date
Application number
SG10201804260QA
Inventor
Nathan E Testa
Christina N Carrigan
Olga Ab
Daniel Tavares
Beni B Wolf
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of SG10201804260QA publication Critical patent/SG10201804260QA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

DIAGNOSTIC ASSAYS AND KITS FOR DETECTION OF FOLATE RECEPTOR 1 The invention generally relates to antibodies that bind to human folate receptor 1 and diagnostic assays for folate receptor 1 -based therapies. Methods of using the antibodies to monitor therapy are further provided. The present invention provides methods for detection of FOLRI in a sample and can be used, for example, to stratify patients. Thus, in one embodiment, the invention provides a method of treating a patient having a folate receptor 1 -mediated disease comprising: (a) measuring the shed folate receptor 1 (FOLRI) expression level or FOLR1 on a circuiting tumor cell (CTC) in a sample taken from a patient. No suitable Fig.
SG10201804260QA 2012-08-31 2013-08-30 Diagnostic assays and kits for detection of folate receptor 1 SG10201804260QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261695791P 2012-08-31 2012-08-31
US201361756254P 2013-01-24 2013-01-24

Publications (1)

Publication Number Publication Date
SG10201804260QA true SG10201804260QA (en) 2018-07-30

Family

ID=50184673

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201500938XA SG11201500938XA (en) 2012-08-31 2013-08-30 Diagnostic assays and kits for detection of folate receptor 1
SG10201804260QA SG10201804260QA (en) 2012-08-31 2013-08-30 Diagnostic assays and kits for detection of folate receptor 1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201500938XA SG11201500938XA (en) 2012-08-31 2013-08-30 Diagnostic assays and kits for detection of folate receptor 1

Country Status (27)

Country Link
US (6) US9200073B2 (en)
EP (2) EP3712175A1 (en)
JP (6) JP6293147B2 (en)
KR (4) KR20150046316A (en)
CN (2) CN110294805B (en)
AU (4) AU2013308497B2 (en)
BR (1) BR112015004229B1 (en)
CA (2) CA3137438A1 (en)
CY (1) CY1122907T1 (en)
DK (1) DK2890717T3 (en)
ES (1) ES2788151T3 (en)
HK (1) HK1210188A1 (en)
HR (1) HRP20200482T1 (en)
HU (1) HUE049693T2 (en)
IL (4) IL299620A (en)
LT (1) LT2890717T (en)
ME (1) ME03799B (en)
MX (1) MX362514B (en)
NZ (2) NZ630433A (en)
PL (1) PL2890717T3 (en)
PT (1) PT2890717T (en)
RS (1) RS60217B1 (en)
RU (1) RU2668824C2 (en)
SG (2) SG11201500938XA (en)
SI (1) SI2890717T1 (en)
WO (1) WO2014036495A2 (en)
ZA (1) ZA201707245B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103037900B (en) 2010-02-24 2016-04-06 伊缪诺金公司 Folacin receptor 1 antibody and immunoconjugates with and uses thereof
EP2694106B1 (en) * 2011-04-01 2017-12-13 ImmunoGen, Inc. Methods for increasing efficacy of folr1 cancer therapy
RU2668824C2 (en) 2012-08-31 2018-10-02 Иммьюноджен Инк. Diagnostic assays and kits for detection of folate receptor 1
US20160311921A1 (en) * 2013-06-20 2016-10-27 Morphotek ,Inc. Methods for treatment of ovarian cancer
BR112016003665B1 (en) 2013-08-30 2024-01-09 Immunogen, Inc ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF THAT SPECIFICALLY BINDS TO A FOLATE 1 RECEPTOR EPITOPEY, POLYNUCLEOTIDE, VECTOR, PROKARYOTIC OR YEAST HOST CELL, COMPOSITION, ITS USES AND IN VITRO METHODS FOR DETECTING FOLATE 1 RECEPTOR EXPRESSION AND IDENTIFICATION OF A CANCER
CN106164093A (en) * 2013-10-08 2016-11-23 伊缪诺金公司 Anti-FOLR1 immune conjugate dosage regimen
US20150297744A1 (en) * 2014-03-28 2015-10-22 Immunogen, Inc. Anti-FOLR1 Immunoconjugate Dosing Regimens
JPWO2015186823A1 (en) * 2014-06-06 2017-04-20 協和発酵キリン株式会社 Treatment method and medicine for cancer patient with FOLR1 target drug and antifolate
EA201791121A1 (en) * 2014-11-20 2018-04-30 Ф. Хоффманн-Ля Рош Аг ACTIVATING T-CELL BISPECIFIC ANTIGEN-BINDING MOLECULES AGAINST FOLRI AND CD3
US10172875B2 (en) 2015-09-17 2019-01-08 Immunogen, Inc. Therapeutic combinations comprising anti-FOLR1 immunoconjugates
CN105548059B (en) * 2016-01-29 2018-08-24 福建医科大学 Folic acid-bovine serum albumin(BSA)-platinum bismuth nanocomposite
WO2017192863A1 (en) * 2016-05-04 2017-11-09 L.E.A.F. Holdings Group Llc Targeted liposomal gemcitabine compositions and methods thereof
US10822410B2 (en) 2016-11-23 2020-11-03 Eisai R&D Management Co., Ltd. Anti-folate receptor alpha antibodies and uses thereof
CN108982430B (en) * 2017-05-31 2020-09-29 北京大学 Kit and method for marking bacterial flora sample and application
CN111108385A (en) * 2017-09-05 2020-05-05 伊缪诺金公司 Method for detecting folate receptor 1 in a patient sample
EA202092125A1 (en) 2018-03-13 2020-12-15 Фейнз Терапьютикс, Инк. ANTIBODIES AGAINST FOLATE 1 RECEPTOR AND THEIR APPLICATION
JP2022526841A (en) * 2019-04-12 2022-05-26 フェインズ セラピューティクス，インコーポレーテッド Humanized antifolate receptor 1 chimeric antigen receptor and its use
WO2020223221A1 (en) 2019-04-29 2020-11-05 Immunogen, Inc. Biparatopic fr-alpha antibodies and immunoconjugates
CN112794911B (en) * 2021-04-14 2021-08-03 上海偌妥生物科技有限公司 Humanized anti-folate receptor 1 antibody and application thereof
CN114163520B (en) * 2021-11-23 2024-01-30 南京京达生物技术有限公司 Preparation method of hematogenous human IgM antibody purification medium
CN117700556B (en) * 2024-02-05 2024-04-12 苏州百道医疗科技有限公司 anti-FR alpha mouse monoclonal antibody and application thereof
CN117700557B (en) * 2024-02-05 2024-04-30 卡秋(江苏)生物科技有限公司 Antibody or antigen binding fragment specifically binding to folate receptor alpha

Family Cites Families (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2031216A1 (en) 1969-06-19 1971-01-14 Citizen Watch Co Ltd , Tokio Day and date setting device for clocks with calendar
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3587814T2 (en) 1985-03-30 1994-11-10 Marc Ballivet METHOD FOR OBTAINING DNA, RNS, PEPTIDES, POLYPEPTIDES OR PROTEINS BY THE DNA RECOMBINANT METHOD.
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (en) 1986-01-15 1987-07-16 Ant Nachrichtentech METHOD FOR DECODING BINARY SIGNALS AND VITERBI DECODERS AND APPLICATIONS
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5763192A (en) 1986-11-20 1998-06-09 Ixsys, Incorporated Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
JP3040121B2 (en) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド Methods of treating tumor cells by inhibiting growth factor receptor function
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
GB8826530D0 (en) 1988-11-12 1988-12-14 Ped Capacitors Ltd Electrical capacitors
US20040049014A1 (en) 1988-12-28 2004-03-11 Protein Design Labs, Inc. Humanized immunoglobulins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
WO1990014443A1 (en) 1989-05-16 1990-11-29 Huse William D Co-expression of heteromeric receptors
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
DE69133566T2 (en) 1990-01-12 2007-12-06 Amgen Fremont Inc. Formation of xenogenic antibodies
US6916605B1 (en) 1990-07-10 2005-07-12 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
WO1992003461A1 (en) 1990-08-24 1992-03-05 Ixsys, Inc. Methods of synthesizing oligonucleotides with random codons
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
KR100272077B1 (en) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
CA2098824A1 (en) 1990-12-20 1992-06-21 William D. Huse Optimization of binding proteins
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
ES2341666T3 (en) 1991-12-02 2010-06-24 Medimmune Limited PRODUCTION OF AUTHORTIC BODIES OF REPERTORIES OF ANTIQUE RPOS SEGMENTS EXPRESSED ON THE FAGOS SURFACE.
JP4157160B2 (en) 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド Methods for the preparation of modified antibody variable regions
WO1993017715A1 (en) 1992-03-05 1993-09-16 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US20030148406A1 (en) 1992-03-17 2003-08-07 David John King Multivalent antigen-binding proteins
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
WO1994018219A1 (en) 1993-02-02 1994-08-18 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
KR20050085971A (en) 1995-04-27 2005-08-29 아브게닉스, 인크. Human antibodies derived from immunized xenomice
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6706484B1 (en) 1995-08-18 2004-03-16 Morphosys Ag Protein/(poly)peptide libraries
JP4436457B2 (en) 1995-08-18 2010-03-24 モルフォシス アイピー ゲーエムベーハー Protein / (poly) peptide library
JP2002514895A (en) 1995-09-28 2002-05-21 アレクション、ファーマスーティカルズ、インコーポレーテッド Pig cell interacting protein
US6331431B1 (en) 1995-11-28 2001-12-18 Ixsys, Inc. Vacuum device and method for isolating periplasmic fraction from cells
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
EP2314625B1 (en) 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US6596850B1 (en) 1998-01-30 2003-07-22 Ixsys, Incorporated Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
AU8691398A (en) 1997-08-04 1999-02-22 Ixsys, Incorporated Methods for identifying ligand specific binding molecules
CA2354862A1 (en) 1998-10-19 2000-04-27 Yeda Research And Development Co. Ltd. Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens
US20040031072A1 (en) 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
CA2339889C (en) 1999-07-02 2012-01-31 Morphosys Ag Identification of specific binding partners binding to (poly)peptides encoded by genomic dna fragments or ests
IT1307309B1 (en) 1999-12-30 2001-10-30 Enea Ente Nuove Tec STABILIZING PEPTIDES, POLYPEPTIDES AND ANTIBODIES THAT INCLUDE THEM.
CZ304942B6 (en) 2000-03-31 2015-02-04 Purdue Research Foundation Medicament for increasing specific elimination of tumor cell population and pharmaceutical composition containing phosphate-FITC conjugate or phosphate-dinitrophenyl
DE10037759A1 (en) 2000-08-03 2002-07-04 Gruenenthal Gmbh screening process
KR100899970B1 (en) 2001-02-19 2009-05-28 메르크 파텐트 게엠베하 Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
AU2002258518A1 (en) 2001-03-14 2002-09-24 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
EP1390077B1 (en) 2001-05-02 2014-07-16 Purdue Research Foundation Treatment and diagnosis of macrophage mediated disease
US7314974B2 (en) 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
WO2003074704A1 (en) 2002-03-01 2003-09-12 Japan Envirochemicals, Ltd. Proteins capable of binding to female sex hormones and process for producing the same
WO2003089475A2 (en) 2002-04-22 2003-10-30 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Antibodies, recombinant antibodies, recombinant antibody fragments and fusions mediated plant disease resistance against fungi
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
AU2003295411A1 (en) 2002-11-07 2004-06-03 Celltech R & D Human monoclonal antibodies to heparanase
CN1795009B (en) 2002-11-07 2014-07-09 伊谬诺金公司 Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same
EP1481993A1 (en) 2003-05-28 2004-12-01 Xerion Pharmaceuticals AG Modulation of the poliovirus receptor function
US20050255114A1 (en) 2003-04-07 2005-11-17 Nuvelo, Inc. Methods and diagnosis for the treatment of preeclampsia
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
JP5416338B2 (en) 2003-05-09 2014-02-12 デューク ユニバーシティ CD20-specific antibody and method of use thereof
KR101424624B1 (en) 2003-05-14 2014-07-31 이뮤노젠 아이엔씨 Drug Conjugate Composition
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
JP2008500949A (en) 2003-07-02 2008-01-17 ジェネンテック・インコーポレーテッド Compositions and methods for tumor diagnosis and treatment
CA2548942C (en) 2003-12-05 2013-10-15 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health Anti-sars monoclonal antibodies
JP4805848B2 (en) * 2004-02-12 2011-11-02 モルフォテック、インク． Monoclonal antibodies that specifically block the biological activity of tumor antigens
US20080187954A1 (en) 2004-03-10 2008-08-07 Lonza Ltd. Method For Producing Antibodies
ES2427177T3 (en) 2004-04-27 2013-10-29 Galapagos N.V. Methods, agents and tests for the detection of compounds to induce differentiation of undifferentiated mammalian cells to give rise to osteoblasts
AU2005279347A1 (en) 2004-08-30 2006-03-09 Lonza Biologics Plc. Affinity- plus ion exchange- chromatography for purifying antibodies
US7776869B2 (en) 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
EP2465872A3 (en) 2004-10-25 2012-12-19 Merck Sharp & Dohme Corporation Anti-ADDL antibodies and uses thereof
EP2562259B1 (en) 2004-12-21 2016-07-06 Monsanto Technology LLC Transgenic plants with enhanced agronomic traits
EA200701211A1 (en) 2004-12-31 2007-12-28 Дженентек, Инк. POLYPEPTIDES THAT ARE BINDING WITH BR3, AND THEIR APPLICATION
CA2594297A1 (en) 2005-01-27 2006-07-27 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US7608413B1 (en) 2005-03-25 2009-10-27 Celera Corporation Kidney disease targets and uses thereof
PT1866339E (en) 2005-03-25 2013-09-03 Gitr Inc Gitr binding molecules and uses therefor
ATE460668T1 (en) 2005-03-30 2010-03-15 Purdue Research Foundation METHOD FOR PREDICTING BREAST CANCER USING QUANTIFICATION OF CELLULAR FOLATE VITAMIN RECEPTORS
EP1879922A2 (en) 2005-04-22 2008-01-23 Morphotek, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
JP2008539693A (en) 2005-05-12 2008-11-20 オンコセラピー・サイエンス株式会社 Method for damaging cells using effector function of anti-DSC2 antibody
EP1915394B1 (en) 2005-05-20 2021-01-27 Lonza Biologics plc. High-level expression of recombinant antibody in a mammalian host cell
MX2007014673A (en) 2005-05-24 2008-04-08 Avestha Gengraine Tech Pvt Ltd A method for the production of a monoclonal antibody to cd20 for the treatment of b-cell lymphoma.
JP5175723B2 (en) 2005-07-05 2013-04-03 パーデュー・リサーチ・ファウンデーション Preparation of compositions for treating monocyte-mediated diseases
US7521195B1 (en) 2005-07-21 2009-04-21 Celera Corporation Lung disease targets and uses thereof
EP1937720B1 (en) 2005-08-18 2014-04-09 Ramot at Tel-Aviv University Ltd. Single chain antibodies against beta-amyloid peptide
CA2621363C (en) 2005-09-13 2015-07-07 National Research Council Of Canada Methods and compositions for modulating tumor cell activity
AU2006304605A1 (en) 2005-10-17 2007-04-26 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
RS52860B (en) 2005-12-20 2013-12-31 Sbi Biotech Co. Ltd. Anti-ilt7 antibody
US8486412B2 (en) 2006-06-01 2013-07-16 Mayo Foundation For Medical Education And Research Immunity to folate receptors
JP5564249B2 (en) 2006-06-23 2014-07-30 アレシア・バイオセラピューティクス・インコーポレーテッド Polynucleotide and polypeptide sequences involved in cancer
US7910702B2 (en) 2006-07-28 2011-03-22 The Governors Of The University Of Alberta Recombinant antibodies to sclerotinia antigens
EP2520935A3 (en) 2006-08-09 2013-02-13 Homestead Clinical Corporation Organ-specific proteins and methods of their use
US20090182955A1 (en) 2006-09-08 2009-07-16 Rao Cherukuri Application configuration across client devices of a local system
EP1900752A1 (en) * 2006-09-15 2008-03-19 DOMPE' pha.r.ma s.p.a. Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
NZ576855A (en) 2006-10-12 2012-08-31 Forerunner Pharma Res Co Ltd Diagnosis and treatment of cancer using anti-ereg antibody
EP2103628A4 (en) 2006-12-14 2012-02-22 Forerunner Pharma Res Co Ltd Anti-claudin-3 monoclonal antibody, and treatment and diagnosis of cancer using the same
WO2008076487A2 (en) 2006-12-20 2008-06-26 Verenium Corporation Antibodies and methods for making and using them
US20080227704A1 (en) 2006-12-21 2008-09-18 Kamens Joanne S CXCL13 binding proteins
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
WO2008101231A2 (en) 2007-02-16 2008-08-21 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
EP2604284A1 (en) 2007-02-16 2013-06-19 KTB Tumorforschungsgesellschaft mbH Receptor And Antigen Targeted Prodrug
WO2008145136A1 (en) 2007-05-30 2008-12-04 Aarhus Universitet Stat3 inactivation by inhibition of the folate receptor pathway
WO2009002993A1 (en) 2007-06-25 2008-12-31 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
CN101139613B (en) 2007-08-01 2011-06-08 姜荣锡 Antineoplastic dibasic polypeptide and application and preparation method thereof
US20100330572A1 (en) 2007-12-21 2010-12-30 Assaraf Yehuda G Organic compounds
EP2241578B1 (en) 2008-01-11 2016-04-20 The University of Tokyo Anti-cldn6 antibody
EP2287174B8 (en) 2008-01-18 2016-12-07 Bio-Rad Laboratories, Inc. Enhanced purification of antibody fragments by apatite chromatography
JP5470817B2 (en) 2008-03-10 2014-04-16 日産自動車株式会社 Battery electrode, battery using the same, and manufacturing method thereof
WO2009132031A2 (en) 2008-04-21 2009-10-29 Swapsol Corp. Hydrogen sulfide conversion to hydrogen
WO2009132081A2 (en) 2008-04-24 2009-10-29 The Research Foundation Of State University Of New York Monoclonal antibody-based targeting of folate receptors
KR20220035504A (en) 2008-04-30 2022-03-22 이뮤노젠 아이엔씨 Cross-linkers and their uses
KR20100137585A (en) 2008-04-30 2010-12-30 이뮤노젠 아이엔씨 Potent conjugates and hydrophilic linkers
US8383351B2 (en) 2008-06-11 2013-02-26 Oxford Brookes University Antibody to inhibin/ activin β-B subunit
US20100069298A1 (en) * 2008-09-16 2010-03-18 Robert Penny Methods for Detecting Overexpression of SPARC and Therapeutic and Diagnostic Methods Relating to Same
NZ592255A (en) 2008-09-17 2013-07-26 Endocyte Inc Folate receptor binding conjugates of antifolates
US20100092470A1 (en) 2008-09-22 2010-04-15 Icb International, Inc. Antibodies, analogs and uses thereof
CN101440130B (en) 2008-11-21 2011-07-27 中国人民解放军第四军医大学 Variable regions of heavy chain and light chain of antihuman IL-13R alpha 2 monoclonal antibody
EP2995953B1 (en) 2009-03-24 2017-11-29 Biocept, Inc. Devices and methods of cell capture and analysis
ES2624835T3 (en) * 2009-08-06 2017-07-17 Immunas Pharma, Inc. Antibodies that specifically bind to the A beta oligomers and use thereof
US9175086B2 (en) 2010-02-10 2015-11-03 Immunogen, Inc. CD20 antibodies and uses thereof
CN103037900B (en) 2010-02-24 2016-04-06 伊缪诺金公司 Folacin receptor 1 antibody and immunoconjugates with and uses thereof
RU2013122843A (en) * 2010-10-20 2014-11-27 Морфотек, Инк. Glycoforms of Antibodies Against Folate Alpha Receptor
KR102057438B1 (en) * 2010-11-05 2019-12-20 에이자이 아이엔씨. Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers
BR112013025228A2 (en) 2011-03-29 2018-09-25 Immunogen Inc process for making improved homogeneity conjugates
SI2691155T1 (en) 2011-03-29 2019-03-29 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
EP2694106B1 (en) 2011-04-01 2017-12-13 ImmunoGen, Inc. Methods for increasing efficacy of folr1 cancer therapy
US20120282282A1 (en) 2011-04-04 2012-11-08 Immunogen, Inc. Methods for Decreasing Ocular Toxicity of Antibody Drug Conjugates
LT2731972T (en) * 2011-07-15 2018-03-26 Eisai R&D Management Co., Ltd. Anti-folate receptor alpha antibodies and uses thereof
RU2668824C2 (en) 2012-08-31 2018-10-02 Иммьюноджен Инк. Diagnostic assays and kits for detection of folate receptor 1
CN104884617B (en) 2012-12-07 2019-02-19 协和发酵麒麟株式会社 Anti- FOLR1 antibody
JP6136279B2 (en) 2013-01-15 2017-05-31 株式会社ジェイテクト Rolling bearing device
TWI503850B (en) 2013-03-22 2015-10-11 Polytronics Technology Corp Over-current protection device
KR20240068778A (en) 2013-05-14 2024-05-17 이뮤노젠 아이엔씨 Anti-folr1 immunoconjugate dosing regimens
BR112016003665B1 (en) 2013-08-30 2024-01-09 Immunogen, Inc ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF THAT SPECIFICALLY BINDS TO A FOLATE 1 RECEPTOR EPITOPEY, POLYNUCLEOTIDE, VECTOR, PROKARYOTIC OR YEAST HOST CELL, COMPOSITION, ITS USES AND IN VITRO METHODS FOR DETECTING FOLATE 1 RECEPTOR EXPRESSION AND IDENTIFICATION OF A CANCER
TWI510996B (en) 2013-10-03 2015-12-01 Acer Inc Methods for controlling a touch panel and portable computers using the same
CN106164093A (en) 2013-10-08 2016-11-23 伊缪诺金公司 Anti-FOLR1 immune conjugate dosage regimen
US20150297744A1 (en) 2014-03-28 2015-10-22 Immunogen, Inc. Anti-FOLR1 Immunoconjugate Dosing Regimens
US10172875B2 (en) 2015-09-17 2019-01-08 Immunogen, Inc. Therapeutic combinations comprising anti-FOLR1 immunoconjugates
US9816280B1 (en) 2016-11-02 2017-11-14 Matthew Reitnauer Portable floor

Also Published As

Publication number Publication date
JP7289346B2 (en) 2023-06-09
BR112015004229A2 (en) 2017-08-08
IL299620A (en) 2023-03-01
AU2018203934A1 (en) 2018-06-21
JP2023111942A (en) 2023-08-10
CA2883222A1 (en) 2014-03-06
US20230213524A1 (en) 2023-07-06
SI2890717T1 (en) 2020-07-31
BR112015004229B1 (en) 2023-02-07
US9702881B2 (en) 2017-07-11
US10180432B2 (en) 2019-01-15
JP2022022420A (en) 2022-02-03
KR20210145850A (en) 2021-12-02
ES2788151T3 (en) 2020-10-20
DK2890717T3 (en) 2020-05-11
WO2014036495A2 (en) 2014-03-06
MX362514B (en) 2019-01-22
CN110294805B (en) 2023-08-15
IL280634A (en) 2021-03-25
CA3137438A1 (en) 2014-03-06
ME03799B (en) 2021-04-20
US10613093B2 (en) 2020-04-07
PT2890717T (en) 2020-04-22
US20190227073A1 (en) 2019-07-25
EP2890717B1 (en) 2020-03-04
AU2018203934B2 (en) 2020-05-07
IL280634B2 (en) 2023-06-01
US20140099332A1 (en) 2014-04-10
JP6293147B2 (en) 2018-03-14
NZ726258A (en) 2019-07-26
IL237087B (en) 2019-05-30
JP2015533788A (en) 2015-11-26
AU2020204602B2 (en) 2023-08-24
CN104755498A (en) 2015-07-01
RS60217B1 (en) 2020-06-30
IL237087A0 (en) 2015-03-31
HUE049693T2 (en) 2020-10-28
LT2890717T (en) 2020-06-10
RU2668824C2 (en) 2018-10-02
AU2013308497A1 (en) 2015-02-26
KR20200079565A (en) 2020-07-03
EP2890717A2 (en) 2015-07-08
US20180003715A1 (en) 2018-01-04
EP2890717A4 (en) 2016-08-03
US20160146824A1 (en) 2016-05-26
AU2013308497B2 (en) 2018-06-28
US9200073B2 (en) 2015-12-01
US20200333347A1 (en) 2020-10-22
RU2015104579A (en) 2016-10-20
KR20240005129A (en) 2024-01-11
CN104755498B (en) 2019-06-18
AU2020204602A1 (en) 2020-07-30
KR20150046316A (en) 2015-04-29
EP3712175A1 (en) 2020-09-23
MX2015002605A (en) 2015-06-10
CA2883222C (en) 2021-12-14
PL2890717T3 (en) 2020-08-10
JP2020018325A (en) 2020-02-06
RU2018133493A (en) 2020-03-24
IL264770B (en) 2021-02-28
SG11201500938XA (en) 2015-04-29
CY1122907T1 (en) 2021-10-29
NZ630433A (en) 2017-10-27
HRP20200482T1 (en) 2020-06-26
CN110294805A (en) 2019-10-01
HK1210188A1 (en) 2016-04-15
WO2014036495A3 (en) 2014-04-10
ZA201707245B (en) 2019-05-29
JP6480558B2 (en) 2019-03-13
JP2018088942A (en) 2018-06-14
AU2023210668A1 (en) 2023-08-31
KR102617499B1 (en) 2023-12-22
JP2018042573A (en) 2018-03-22
WO2014036495A4 (en) 2014-05-08

Similar Documents

Publication Publication Date Title
SG10201804260QA (en) Diagnostic assays and kits for detection of folate receptor 1
CY1124428T1 (en) ANTIBODIES AND ASSAYS FOR THE DETECTION OF FOLIC ACID RECEPTOR 1
MX2017015260A (en) Anti-gitr antibodies for cancer diagnostics.
BR112012020101A2 (en) diagnostic and therapeutic methods using anti-cd200 antibodies.
BR112015022934A8 (en) neuroactive steroids, compositions and uses of these
MX357740B (en) Methods for treating or predicting risk of a ventricular tachyarrhythmia event.
MX2019015155A (en) Mouse model for assessing toxicities associated with immunotherapies.
GEP201706737B (en) Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy
IN2012DN06309A (en)
MX2016013910A (en) Cancer treatment.
WO2015013508A3 (en) Methods for diagnosing and treating immune disease
PH12015502687A1 (en) Marker for acid sphingomyelinase disorders and uses thereof
TN2012000590A1 (en) Apparatus, method and computer-readable storage medium for evaluating a physiological condition of a patient
MX366272B (en) METHODS and COMPOSITIONS FOR DIAGNOSING PREECLAMPSIA.
WO2013188823A3 (en) Cancer prognostic assays
MX2021000215A (en) Diagnostic assays and kits for detection of folate receptor 1.
EA201001297A1 (en) METHOD FOR DIAGNOSTICS OF HUMAN MELANOMA ON THE BASIS OF DETERMINING THE EXPRESSION LEVEL PHF10 GENE, DIAGNOSTIC KIT
UA93325U (en) Method for diagnosing fracture union
UA93315U (en) Method for diagnosing failure of union in fracture
UA93314U (en) Method for diagnosing failure of union in fracture
UA106254U (en) Method for predicting fracture healing
UA104420U (en) The method of predicting fracture
UA96044U (en) Method for predicting fracture healing
UA93313U (en) Method for diagnosing neoarthrosis
UA93311U (en) Method for diagnosing fracture union